Suppr超能文献

基于 GRL0617 的 SARS-CoV-2 木瓜蛋白酶样蛋白酶抑制剂设计:结构-活性关系。

Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships.

机构信息

Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, SK-83232 Bratislava, Slovakia.

Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, SK-83232 Bratislava, Slovakia.

出版信息

Bioorg Med Chem. 2024 Nov 1;113:117909. doi: 10.1016/j.bmc.2024.117909. Epub 2024 Sep 11.

Abstract

The unique and complex structure of papain-like protease (PL) of the SARS-CoV-2 virus represents a difficult challenge for antiviral development, yet it offers a compelling validated target for effective therapy of COVID-19. The surge in scientific interest in inhibiting this cysteine protease emerged after its demonstrated connection to the cytokine storm in patients with COVID-19 disease. Furthermore, the development of new inhibitors against PL may also be beneficial for the treatment of respiratory infections caused by emerging coronavirus variants of concern. This review article provides a comprehensive overview of PL inhibitors, focusing on the structural framework of the known inhibitor GRL0617 and its analogs. We categorize PL inhibitors on the basis of their structures and binding site: Glu167 containing site, BL2 groove, Val70 site, and Cys111 containing catalytic site. We summarize and evaluate the majority of GRL0617-like inhibitors synthesized so far, highlighting their published biochemical parameters, which reflect their efficacy. Published research has shown that strategic modifications to GRL0617, such as decorating the naphthalene ring, extending the aromatic amino group or the orthomethyl group, can substantially decrease the IC from micromolar up to nanomolar concentration range. Some advantageous modifications significantly enhance inhibitory activity, paving the way for the development of new potent compounds. Our review places special emphasis on structures that involve direct modifications to the GRL0617 scaffold, including piperidine carboxamides and modified benzylmethylnaphthylethanamines (Jun9 scaffold). All these compounds are believed to inhibit the proteolytic, deubiquitination, and deISGylation activity of PL, biochemical processes linked to the severe progression of COVID-19. Finally, we summarize the development efforts for SARS-CoV-2 PL inhibitors, in detailed structure-activity relationships diagrams. This aims to inform and inspire future research in the search for potent antiviral agents against PL of current and emerging coronavirus threats.

摘要

新型冠状病毒木瓜样蛋白酶(PL)独特而复杂的结构对抗病毒药物的研发构成了巨大挑战,但它是治疗 COVID-19 的有效药物的一个极具吸引力的验证靶点。在发现这种半胱氨酸蛋白酶与 COVID-19 患者的细胞因子风暴有关后,科学界对其抑制作用的研究兴趣迅速增加。此外,开发针对 PL 的新型抑制剂也可能有益于治疗由新型冠状病毒关切变异株引起的呼吸道感染。本文综述了 PL 抑制剂,重点介绍了已知抑制剂 GRL0617 及其类似物的结构框架。我们根据抑制剂的结构和结合位点对其进行分类:Glu167 结合位点、BL2 沟、Val70 结合位点和含 Cys111 的催化位点。我们总结和评估了迄今为止合成的大多数 GRL0617 类似物抑制剂,突出了其已发表的生化参数,反映了它们的疗效。研究表明,对 GRL0617 进行策略性修饰,例如修饰萘环、延长芳族氨基或邻甲基,可以将 IC50 从微摩尔降低到纳摩尔浓度范围。一些有利的修饰显著提高了抑制活性,为开发新的有效化合物铺平了道路。本文特别强调了涉及对 GRL0617 骨架进行直接修饰的结构,包括哌啶甲酰胺和修饰的苄基甲基萘乙胺(Jun9 骨架)。所有这些化合物都被认为可以抑制 PL 的蛋白水解、去泛素化和去 ISG 化活性,这些生化过程与 COVID-19 的严重进展有关。最后,我们总结了 SARS-CoV-2 PL 抑制剂的开发工作,以详细的结构-活性关系图呈现。这旨在为针对当前和新兴冠状病毒威胁的 PL 寻找有效的抗病毒药物的未来研究提供信息和启发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验